Iteos Competitors

Delisted . USA . 
Stock . Iteos Therapeutics
ITOSDelisted Stock  USD 10.15  0.00  0.00%   
Iteos Therapeutics competes with Invivyd, Sinovac Biotech, and Climb Bio; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Iteos Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Iteos Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Iteos Therapeutics vs G1 Therapeutics Correlation

Moving against Iteos Stock

  0.39T ATT Inc Aggressive PushPairCorr
  0.31ORGN Origin MaterialsPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
10.1510.1510.15
Details
Intrinsic
Valuation
LowRealHigh
8.638.6311.17
Details
Naive
Forecast
LowNextHigh
10.1310.1310.13
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
9.9810.1410.30
Details

Iteos Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Iteos Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Iteos and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Iteos Therapeutics does not affect the price movement of the other competitor.

High positive correlations

CLYM
+ 0.85
SAGE
VIGL
+ 0.76
CKPT
CKPT
+ 0.64
IVVD
VIGL
+ 0.57
CLYM
VIGL
+ 0.52
IVVD
CLYM
+ 0.47
CKPT
  

High negative correlations

VIGL
- 0.7
RVNC
CKPT
- 0.68
RVNC
RVNC
- 0.66
IVVD
CLYM
- 0.48
RVNC
SAGE
- 0.31
RVNC
GTHX
- 0.0
BCYP

Risk-Adjusted Indicators

There is a big difference between Iteos Stock performing well and Iteos Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Iteos Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
IVVD  4.97  0.23  0.03 (4.17) 5.64 
(5.53)
 11.11 
(8.57)
 46.37 
SVA  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
RVNC  3.04 (0.59) 0.00 (0.27) 0.00 
 0.00 
 6.38 
(5.97)
 40.39 
CKPT  2.14  0.80  0.26  0.97  1.42 
(2.97)
 2.33 
(2.52)
 62.14 
SAGE  1.96  0.28  0.10 (0.57) 1.70 
(2.63)
 3.61 
(3.48)
 37.83 
CLYM  6.03  1.68  0.29  2.12  5.02 
(7.36)
 14.49 
(8.38)
 42.56 
VIGL  7.50  3.90  0.82 (0.58) 1.63 
(9.75)
 5.09 
(2.49)
 241.38 
ORTX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
BCYP  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
GTHX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 

Iteos Therapeutics Competitive Analysis

The better you understand Iteos Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Iteos Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Iteos Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ITOS IVVD SVA RVNC CKPT SAGE CLYM VIGL
 0.00 
 10.15 
Iteos
 2.13 
 1.84 
Invivyd
 0.00 
 6.47 
Sinovac
 0.00 
 3.65 
Revance
 0.47 
 4.26 
Checkpoint
 0.00 
 8.68 
Sage
 1.94 
 5.05 
Climb
 0.00 
 8.05 
Vigil
Market Volatility
(90 Days Market Risk)
Very steady
Very risky
Very steady
Very steady
Very steady
Very steady
Risky
Very steady
Market Performance
(90 Days Performance)
Weakest
Mild
Weakest
Weakest
Weakest
Weakest
Solid
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Hazard
High
Small
Hazard
Hazard
Hazard
Average
Hazard
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Buy
Not Available
Not Available
Not Available
Not Available
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Strong Hold
Not Rated
Not Rated
Not Rated
Cautious Hold
Not Rated
Current Ratio
6.42 X
9.14 X
2.98 X
3.38 X
1.30 X
17.69 X
N/A
21.35 X
Net Asset
686.98 M
129.51 M
13.66 B
478.45 M
7.47 M
547.22 M
217.19 M
117.69 M
Profit Margin
N/A
(1.20) %
0.22 %
(0.72) %
N/A
N/A
N/A
N/A
EBITDA
(121.82 M)
(173.76 M)
(6.03 M)
(290.64 M)
(56.17 M)
(409.49 M)
(30.36 M)
(83.8 M)
Current Valuation
(61.62 M)
408.37 M
297.09 M
680.39 M
337.66 M
190.79 M
236.19 M
321.16 M
Price To Book
0.91 X
5.68 X
1.82 X
12.30 X
22.75 X
1.48 X
1.99 X
9.11 X
Operating Margin
N/A
(0.84) %
0.42 %
(0.54) %
N/A
(1.71) %
N/A
N/A
Retained Earnings
(9.78 M)
(901.99 M)
7.12 B
(2.08 B)
(370.57 M)
(2.97 B)
(229.88 M)
(307.03 M)
Current Asset
N/A
N/A
128.52 M
208.68 M
46.85 M
188.49 M
N/A
N/A
Beta
1.49
0.6
0.0649
0.95
1.14
0.3
-0.15
3.34
Number Of Employees
173
99
1.96 K
597
24
353
17
67
Shares Outstanding
44.21 M
281.99 M
99.29 M
104.39 M
86.32 M
62.78 M
47.74 M
46.67 M
Cash Flow From Operations
(98.18 M)
(170.49 M)
106.02 M
(216.57 M)
(31.1 M)
(267.19 M)
(15.56 M)
(51.22 M)
Annual Yield
N/A
N/A
8.50 %
N/A
N/A
N/A
N/A
N/A
Total Debt
5.1 M
1.3 M
298.98 M
478.43 M
20.1 M
11.84 M
532 K
12.95 M
Return On Equity
-0.35
-0.68
0.25
-20.97
-18.7
-0.6
-0.26
-1.46
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.18
-0.26
0.11
-0.24
-1.53
-0.34
-0.17
-0.62
Number Of Shares Shorted
2.06 M
21.41 M
82.76 K
4.51 M
2.96 M
2.22 M
1.8 M
447.39 K
Book Value Per Share
12.90 X
0.43 X
7.52 X
(1.55) X
0.20 X
5.89 X
2.60 X
0.86 X
Current Liabilities
N/A
N/A
58 M
17.52 M
2.89 M
15.31 M
N/A
N/A
Total Asset
686.98 M
129.51 M
13.66 B
478.45 M
7.47 M
547.22 M
217.19 M
117.69 M
Debt To Equity
0.01 %
0 %
0.28 %
2.94 %
0.1 %
0.01 %
N/A
0 %
Short Ratio
1.34 X
4.75 X
N/A
1.70 X
3.18 X
0.65 X
0.80 X
0.56 X
Target Price
10.35
10.0
3.52
9.47
4.45
8.58
9.5
8.0
Shares Owned By Institutions
90.28 %
75.03 %
32.02 %
87.45 %
42.18 %
83.59 %
43.34 %
69.90 %
Market Capitalization
448.68 M
530.14 M
642.44 M
381.02 M
370.71 M
544.94 M
351.15 M
375.71 M
Price To Earning
50.50 X
N/A
48.65 X
(7.60) X
(7.60) X
3.07 X
N/A
N/A
Price To Earnings To Growth
N/A
N/A
N/A
(0.64) X
N/A
0.74 X
N/A
N/A
Price To Sales
12.78 X
10.59 X
1.83 X
1.48 X
9,042 X
7.74 X
N/A
N/A
Net Income
(134.41 M)
(169.93 M)
(258.36 M)
(323.99 M)
(56.24 M)
(400.67 M)
(73.9 M)
(84.26 M)
Earnings Per Share
(4.73) X
(0.45) X
0.97 X
(3.34) X
(1.28) X
(4.89) X
(0.59) X
(2.10) X
Shares Owned By Insiders
0.34 %
11.28 %
51.42 %
8.55 %
14.05 %
10.36 %
0.79 %
18.16 %
Revenue
35 M
25.38 M
448.27 M
234.04 M
41 K
41.24 M
N/A
N/A
Working Capital
469.18 M
38.7 M
10.68 B
249.64 M
(12.62 M)
459.69 M
149.94 M
66.44 M
Cash And Equivalents
791.86 M
418.67 M
176.72 M
233.82 M
30.89 M
1.51 B
N/A
148.91 M
Cash Per Share
22.26 X
3.84 X
1.79 X
3.20 X
0.33 X
25.47 X
N/A
5.27 X
Gross Profit
N/A
46.71 M
443.44 M
103.69 M
(31.4 M)
(75.23 M)
N/A
N/A
Day Typical Price
10.15
1.86
6.47
3.65
4.26
8.68
5.22
8.05
Accumulation Distribution
N/A
299397.0
N/A
N/A
0.0117
N/A
96419.14
N/A
Market Facilitation Index
N/A
N/A
N/A
N/A
0.05
N/A
0.0
N/A
Daily Balance Of Power
0.0
(0.21)
0.0
0.0
0.4
0.0
(0.17)
0.0
Period Momentum Indicator
N/A
(0.04)
N/A
N/A
0.02
N/A
(0.10)
N/A
Rate Of Daily Change
1.0
0.98
1.0
1.0
1.0
1.0
0.98
1.0
Day Median Price
10.15
1.87
6.47
3.65
4.26
8.68
5.3
8.05
Price Action Indicator
N/A
(0.04)
N/A
N/A
0.015
N/A
(0.30)
N/A
Coefficient Of Variation
3829.2
3175.66
N/A
(1,353)
905.43
1816.42
473.82
834.85
Mean Deviation
0.3865
4.97
N/A
3.04
2.14
1.96
6.03
7.5
Jensen Alpha
0.0076
0.2329
N/A
(0.59)
0.7992
0.2766
1.68
3.9
Total Risk Alpha
(0.04)
(0.33)
N/A
(0.98)
0.2719
(0.10)
1.11
1.35
Sortino Ratio
(0.1)
0.0291
N/A
N/A
0.2647
0.0981
0.2896
0.816
Downside Variance
0.263
36.31
N/A
N/A
8.96
4.06
33.06
18.49
Standard Deviation
0.58
7.62
N/A
6.54
7.76
4.76
8.19
29.83
Kurtosis
2.23
6.02
N/A
15.23
58.48
46.7
2.32
64.74
Potential Upside
1.09
11.11
N/A
6.38
2.33
3.61
14.49
5.09
Treynor Ratio
(0.12)
(4.17)
N/A
(0.27)
0.9724
(0.57)
2.12
(0.58)
Maximum Drawdown
3.17
46.37
N/A
40.39
62.14
37.83
42.56
241.38
Variance
0.3364
58.05
N/A
42.72
60.16
22.7
67.15
889.72
Market Risk Adjusted Performance
(0.11)
(4.16)
N/A
(0.26)
0.9824
(0.56)
2.13
(0.57)
Risk Adjusted Performance
0.0165
0.0322
N/A
(0.05)
0.0903
0.049
0.1643
0.0979
Skewness
0.8396
1.86
N/A
(2.30)
7.39
6.3
1.22
8.01
Semi Deviation
0.4282
5.64
N/A
N/A
1.42
1.7
5.02
1.63
Information Ratio
(0.09)
0.023
N/A
(0.08)
0.1021
0.0415
0.2032
0.1176
Value At Risk
(0.79)
(8.57)
N/A
(5.97)
(2.52)
(3.48)
(8.38)
(2.49)
Expected Short fall
(0.55)
(5.53)
N/A
N/A
(2.97)
(2.63)
(7.36)
(9.75)
Downside Deviation
0.5128
6.03
N/A
N/A
2.99
2.02
5.75
4.3
Semi Variance
0.1833
31.79
N/A
N/A
2.03
2.88
25.19
2.66

Iteos Therapeutics Competition Performance Charts

Five steps to successful analysis of Iteos Therapeutics Competition

Iteos Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Iteos Therapeutics in relation to its competition. Iteos Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Iteos Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Iteos Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Iteos Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Iteos Therapeutics position

In addition to having Iteos Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Artificial Intelligence Thematic Idea Now

Artificial Intelligence
Artificial Intelligence Theme
Technology companies, funds, and ETFs across multiple industries that are involved in research or development in the field of reasoning, learning, natural language processing and perception as well as its application to science and commerce. This theme may also include entities involved in cybernetics and cognitive brain simulation field. The Artificial Intelligence theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Artificial Intelligence Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Consideration for investing in Iteos Stock

If you are still planning to invest in Iteos Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Iteos Therapeutics' history and understand the potential risks before investing.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY